NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
NEXGEL (NASDAQ:NXGL) announced it will report fourth quarter and full year 2025 financial results after market close on March 31, 2026.
Rhea-AI Summary
NEXGEL (NASDAQ:NXGL) announced it will report fourth quarter and full year 2025 financial results after market close on March 31, 2026. Management will host a conference call at 4:30 P.M. ET the same day and provide a live webcast and replay.
Dial-in numbers, replay access code 11161124, and a 90-day archived webcast will be available for investors and analysts.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NXGL
On Mar 25, the day this news came out, NXGL closed 0.97% below the previous close.
Data tracked by StockTitan Argus for the Mar 25 session.
Key Figures
- Earnings release date
- March 31, 2026
- Q4 and full-year 2025 financial results announcement
- Conference call time
- 4:30 P.M. ET
- Q4 and full-year 2025 earnings call start time
- Replay availability
- Through April 14, 2026
- Telephone replay window for earnings call
- Webcast archive duration
- 90 days
- Archived webcast availability after the call
Historical Context
-
Detailed financial and strategic terms for Celularity biomaterials acquisition.
-
Signed definitive agreement for revenue-accretive regenerative biomaterials portfolio.
-
Announced $1.797M financing tied to a targeted Q1 2026 acquisition.
-
New investment and strategic advisor for NexGelRx spin-off entity.
-
Announced spin-off of drug delivery program into NexGelRx with royalties and equity.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
otc medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management will host a conference call at 4:30 P.M. ET on the same day
LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on March 31, 2026. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.
Fourth Quarter and Full Year 2025 Financial Results Conference Call
Date: March 31, 2026
Time: 4:30 P.M. ET
Live Call: 1-833-316-1983 (U.S. Toll Free) or 1-785-838-9310 (International)
Webcast: Events and Presentations
For interested individuals unable to join the conference call, a replay will be available through April 14, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11161124. An archived version of the webcast will also be available for 90 days.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.